Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults
Journal of the American Heart Association · 12.11.2026
DOI: 10.1161/jaha.126.053443 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the American Heart Association, online erschienen am 12.11.2026. Verfasst von Sangho Hyun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Lakeland Regional Health Medical Center Lakeland FL USA. Hauptthemen laut MEDLINE: Dyslipidemias, Hypolipidemic Agents, Practice Guidelines as Topic, Cardiology. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
The 2026 American College of Cardiology/American Heart Association dyslipidemia guideline replaces the pooled cohort equations with the atherosclerotic cardiovascular disease component of the Predicting Risk of Cardiovascular Disease Events equations for primary prevention risk estimation and modifies lipid‐lowering therapy (LLT) eligibility by lowering the risk‐based treatment threshold and expanding diabetes and chronic kidney disease criteria. The population‐level impact of this transition is uncertain.
Methods
We analyzed National Health and Nutrition Examination Survey 2021 to 2023 participants aged 40 to 75 years without self‐reported atherosclerotic cardiovascular disease and with available low‐density lipoprotein cholesterol. Survey weights were used to generate national estimates. Guideline‐supported LLT eligibility was assessed under the 2018 pooled cohort equations–based American College of Cardiology/American Heart Association cholesterol framework and the 2026 Predicting Risk of Cardiovascular Disease Events–based American College of Cardiology/American Heart Association dyslipidemia framework. Current LLT use was assessed among guideline‐supported adults.
Results
The analytic sample included 1662 participants, representing 115.05 million US adults. LLT was supported for 42.82 million adults under the 2018 framework and 42.17 million under the 2026 framework, a net decrease of 0.65 million. Reclassification was substantial: 37.42 million remained supported, 5.40 million lost support, 4.75 million newly gained support, and 67.48 million remained unsupported. Among supported adults, current LLT use was 39.4% under the 2018 framework and 40.5% under the 2026 framework.
Conclusions
Transition to the 2026 Predicting Risk of Cardiovascular Disease Events–based framework produced little net change in LLT eligibility but meaningfully changed who was supported for therapy. Persistent undertreatment remains a major implementation gap.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine Lakeland Regional Health Medical Center Lakeland FL USA.
- Department of Cardiology Lakeland Regional Health Medical Center Lakeland FL USA.
ORCID-Profile: Sangho Hyun, Padideh Daneii, Jeffrey L Williams, Joel Fernandez
Zitieren
APA
Hyun, S., Sze, C. H., Singh, S., Daneii, P., Williams, J. L., & Fernandez, J. (2026). Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.053443
Vancouver
Hyun S, Sze CH, Singh S, Daneii P, Williams JL, Fernandez J. Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.053443
BibTeX
@article{Hyun2026,
author = {Hyun, Sangho and Sze, Chia-Hung and Singh, Satyajeet and Daneii, Padideh and Williams, Jeffrey L and Fernandez, Joel},
title = {Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.126.053443}
}
EUVIMED